X
[{"orgOrder":0,"company":"Quellis Biosciences Inc","sponsor":"Catabasis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals Announces Acquisition Of Quellis Biosciences Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Quellis Biosciences Inc","sponsor":"Iontas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"}]
Find Clinical Drug Pipeline Developments & Deals by Quellis Biosciences Inc
Filters
Companies By Therapeutic Area
Details:
Under the terms of the agreement, IONTAS / FJB will provide Quell with a diverse panel of novel target binders, ranging in affinities, to enable Quell to select functional binders for chimeric antigen receptor (CAR) development against undisclosed targets.
Lead Product(s):
Engineered Treg cell therapy product
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Cell and Gene therapy
Recipient:
Iontas
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
March 08, 2021
Details:
Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema.
Lead Product(s):
QLS-215
Therapeutic Area: Genetic Disease
Product Name: QLS-215
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Catabasis Pharmaceuticals
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
January 29, 2021